Browsing by Author "Yang, Shengsheng"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort study
    (AME, 2023) Zhang, Yi; Shen, Guoyi; Xu, Rongyu; Huang, Guozhong; Huang, Zhijun; Duan, Hongbing; Yang, Shengsheng; Zheng, Qingfeng; Yang, Libao; Liu, Rongxing; Ma, Liangyun; Chen, Shaogeng; Yi, Yunfeng; Zhang, Zheming; Li, Kezhi; Birdas, Thomas J.; Koyanagi, Kazuo; Simone, Charles B., II; Surgery, School of Medicine
    Background: Camrelizumab has been demonstrated to be a feasible treatment option for locally advanced esophageal squamous cell carcinoma (ESCC) when combined with neoadjuvant chemotherapy. This trial was conducted to investigate the effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with ESCC in daily practice. Methods: This prospective multicenter observational cohort study was conducted at 13 tertiary hospitals in Southeast China. Patients with histologically or cytologically confirmed ESCC [clinical tumor-node-metastasis (cTNM) stage I-IVA] who had received at least one dose of camrelizumab-containing neoadjuvant therapy were eligible for inclusion. Results: Between June 1, 2020 and July 13, 2022, 255 patients were enrolled and included. The median age was 64 (range, 27 to 82) years. Most participants were male (82.0%) and had clinical stage III-IVA diseases (82.4%). A total of 169 (66.3%) participants underwent surgical resection; 146 (86.4%) achieved R0 resection, and 36 (21.3%) achieved pathological complete response (pCR). Grades 3-5 adverse events (AEs) were experienced by 14.5% of participants. Reactive cutaneous capillary endothelial proliferation occurred in 100 (39.2%) of participants and all were grade 1 or 2. Conclusions: Camrelizumab-containing neoadjuvant therapy has acceptable effectiveness and safety profiles in real-life ESCC patients.